



(19)

Eur päisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 733 357 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
25.09.1996 Bulletin 1996/39

(51) Int. Cl.<sup>6</sup>: **A61K 9/06**, A61K 47/02

(21) Application number: 96104268.6

(22) Date of filing: 18.03.1996

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: 22.03.1995 IT MI950568

(71) Applicant: Dompé S.P.A.  
I-67100 L'Aquila (IT)

(72) Inventors:  
• Boltri, Luigi  
67100 L'Aquila (IT)

• Coppola, Antonietta  
67100 L'Aquila (IT)  
• Gentile, Marco  
67100 L'Aquila (IT)  
• Clavenna, Gaetano  
67100 L'Aquila (IT)

(74) Representative: Minoja, Fabrizio  
Studio Consulenza Brevettuale,  
Via Rossini, 8  
20122 Milano (IT)

(54) **Pharmaceutical formulations in form of thixotropic gel**

(57) The present invention relates to a topical formulation of gel-like consistency, but nebulizable by a mechanical pump, containing colloidal silices as gelifying agent.

**EP 0 733 357 A1**

## Description

The present invention relates to a topical formulation of gel-like consistency, but nebulizable by mechanical pump, containing colloidal silices as gelifying agent.

## PRIOR ART

The preparation of a semi-solid system nebulizable by means of a spray mechanical system seemed up to now to be an unsurmountable problem. In fact, efforts to prepare formulations making use of the conventional, most used gelifying agents lead to the production of gels which, although being highly valid, are absolutely not sprayable. Even making a compromise, namely decreasing the system viscosity, at the most the emission of the product from the mechanical pump is obtained, but not the nebulization. Moreover, decreasing viscosity, the product tends to leak once sprayed on the concerned part.

In the cosmetic field, the so-called gel-sprays exist, which however have an exceedingly low viscosity, thereby tending to leak after the emission, therefore they cannot be even defined gels. Moreover they are usually prepared using acrylates such as Carbopols.

## DISCLOSURE OF THE INVENTION

The present invention overcomes the problems of the prior art, by the use of a high viscosity system, which is nearly semisolid, characterized in that it is destructured by a mechanical stress

The pharmaceutical formulations in form of thixotropic gel of the present invention will contain, besides an active ingredient, a colloidal silica in an amount from 2 to 15% by weight, propylene glycol in an amount from 1 to 10% by weight. Water and any excipients conventionally used in the pharmaceutical techniques, such as surfactants, preservatives, flavouring agents, co-solvents and lipophilic phases can also be present. Particularly preferred surfactants are those belonging to the following classes:

- Sorbitan esters (for example Span 20, Span 40, Span 60, Span 65, Span 80, Span 85);
- Polyoxyethylene sorbitan esters (for example Tween 80, Tween 60, Tween 40, Tween 20);
- Polyoxyethylalkyl ethers (for example Cremophor A, Bryj, Texofor A);
- Polyoxyethylene stearates (for example Myrj 52, Myrj 53).

The pharmaceutical formulations of the invention will preferably contain a colloidal silica having a surface area of 175-225 m<sup>2</sup>/g and an average diameter of 12 nm, in amounts ranging from 2 to 8%, more preferably from 2.5 to 7% by weight.

In the pharmaceutical formulations of the invention, water may be present in an amount ranging from 60 to 97% by weight.

The present invention provides a system characterized by:

- Pseudoplasticity: the viscosity decreases with the increase in the intensity of the applied stress;
- Thixotropy: the viscosity decreases with time, as the applied stress goes on.

The system of the present invention uses as gelifying agent colloidal silices, which are excipients widely used in the topical field as thickening and suspending agents, and in the oral solid as lubricants.

It should be noted that within the definition "colloidal silica" lie several commercial products used as pharmaceutical excipients, whose characteristics can be summarized as follows:

Surface area from 50 to 400 m<sup>2</sup>/g  
Average diameter from 7 to 40 nm.

All of these materials give similar gelification phenomena but, since gelification occurs through adsorption, the surface area characteristics become paramount for the choice of the type and amount of colloidal silica to use.

Suitable silices according to the invention have a surface area ranging from 130 to 300 m<sup>2</sup>/g and an average diameter of 12 nm.

The present invention uses specifically as colloidal silices Aerosils, preferably colloidal silices with characteristics similar to Aerosil 200.

Aerosil characteristics of pseudoplasticity and thixotropy are well known, however up to now said characteristics have not been made use of in order to spray/nebulize a product in the form of gel by the simple pressure of a finger.

## EP 0 733 357 A1

In essentially aqueous systems, aerosils (only) at high concentrations (5-15%) cause the structuration of water through adsorption phenomena, until a consistence of gel (or, more correctly, magma). The Aerosil-Water bond is very mild and it can be cleaved by even slight stresses, such as those caused by a mechanical pump. During the stress, and therefore during the spray, the viscosity of the system remarkably decreases, thereby allowing the nebulization. Once applied to the skin, the sprayed product, no longer stressed, quickly returns to its original state, acquiring back a gel-like consistence.

It is particularly surprising that, when in the formulation of the invention besides Aerosil and water, a less polar solvent is also present, such as glycerol, polyoxyethylene glycol, diethylene glycol monoalkyl ether (Transcutol<sup>TM</sup>), N-methylpyrrolidone, glycofurol, isopropanol, ethylene glycol, propylene glycol, viscosity falls upon the slightest mechanical stress; in the absence of said solvent, such a phenomenon appears less markedly, but anyhow so as not to affect adversely the thixotropic characteristics according to the invention. The use of the propylene glycol is particularly preferred.

The topical gel formulation of the present invention can be administered with a suitable dosage, through doser mechanical pumps which dispense prefixed volumes.

The topical formulations of the present invention can be used, besides for the topical administration on the skin, also for the vaginal, nasal, otological administration, wherein the absence of leakage and the in loco persistence are particularly important.

The gels of the present invention will preferably be dispensed by means of mechanical pump dispensers.

The formulations of the invention can also contain all of the active ingredients whose topical administration is therapeutically effective. Examples of active ingredients which can be used in the formulations of the invention comprise: non-steroidal antiinflammatory agents, such as ketoprofen, ibuprofen (including optical isomers and salts thereof), naproxen, diclofenac, diflunisal, nimesulide, ketorolac, flurbiprofen, indomethacin, acetylsalicylic acid and the like; antifungal drugs such as miconazole, econazole, fluconazole, tyrothricin, antibacterials/antibiotics such as polymyxin, neomycin, kanamycin, gentamycin, tetracycline, meclocycline, clindamycin; antiviral drugs such as acyclovir, cytarabine; corticosteroids; antihistamines; sympathomimetic drugs; antiallergic drugs such as disodium cromoglycate; local anesthetics; cicatrizants; capillary-protective substances; bioflavonoids; retinoids; vitamins; enzymes; growth factors.

Some examples of pharmaceutical and para-pharmaceutical formulations containing active ingredients at therapeutic concentrations are reported hereinbelow. a.i. = active ingredient

### PHARMACEUTICAL FORMULATIONS

#### EXAMPLE 1

a.i.	<u>Ketoprofen Lys</u>	15 g
	colloidal silica	5 g
	propylene glycol	5 g
	Tween 80	0.5 g
	Na nipagin	0.1 g
	Nerolene lavender	0.1 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 2

a.i.	<u>miconazole nitrate</u>	2 g
	propylene glycol	10 g
	colloidal silica	3 g
	esterified polyoxyethylene glycols	3 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	malva perfume	0.5 g
	demin. water q.s. to	100 g

## EXAMPLE 3

a.i.	<u>disodium cromoglycate</u>	4 g
	propylene glycol	5 g
	colloidal silica	5.5 g
	sodium edetate	10 mg
	polysorbate 80	0.5 g
	benzalkonium chloride	10 mg
	menthol	0.3 g
	eucalyptol	0.1 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 4

a.i.	<u>oxymetazoline hydrochloride</u>	0.050 g
	monobasic sodium phosphate	1.020 g
	dibasic sodium phosphate	1.110 g
	EDTA	0.010 g
	propylene glycol	5.0 g
	colloidal silica	5.0 g
	Tween 20	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	menthol	0.4 g
	eucalyptol	0.1 g
	demin. water q.s. to	100 g

EXAMPLE 5

a.i.	<u>menthol</u>	0.4 g
	<u>camphor</u>	0.4 g
	<u>eucalyptol</u>	0.2 g
	sodium phosphate monobasic	1.02 g
	sodium phosphate dibasic	1.11 g
	EDTA	0.01 g
	propylene glycol	8.0 g
	colloidal silica	4.0 g
	polysorbate 80	1.0 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 6

a.i.	<u>tyrothricin</u>	0.02 g
	<u>cetyltrimethylammonium bromide</u>	0.05 g
	<u>benzocaine</u>	0.05 g
	PEG 200	4 g
	colloidal silica	4 g
	ethyl alcohol	5 g
	Cremophor A11	0.7 g
	sodium saccharine	0.02 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	peppermint oil	0.5 g
	demin. water q.s. to	100 g

EXAMPLE 7

a.i.	<u>polymixin B sulfate</u>	1.000.000 I.U.
	<u>neomycin sulfate</u>	0.5 g
	<u>Lidocaine chloride</u>	4 g
	propylene glycol	10 g
	colloidal silica	3 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	rose essence	0.2 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 8

5

10

15

a.i.	<u>fluocinolone acetonide</u>	0.025 g
	propylene glycol	10 g
	colloidal silica	4 g
	glyceryl monostearate self-emulsifier	4 g
	Span 60	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lavender essence	0.2 g
	demin. water q.s. to	100 g

20

EXAMPLE 9

25

30

35

a.i.	<u>betametasone valerate</u>	0.1 g
	propylene glycol	5 g
	colloidal silica	5 g
	isopropyl alcohol	5 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lavender essence	0.1 g
	demin. water q.s. to	100 g

40

45

50

55

EP 0 733 357 A1

EXAMPLE 10

a.i.	<u>meclocycline anhydrous sulfosalicylate</u>	2.914 g
	propylene glycol	4 g
	glycerin U.P.	1 g
	colloidal silica	3.5 g
	esterified polyoxyethylene glycols	3 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	rose essence	0.2 g
	demin. water q.s. to	100 g

EXAMPLE 11

a.i.	<u>naproxene</u>	10 g
	colloidal silica	5 g
	ethyl alcohol	10 g
	polysorbate 80	0.75 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	camphor	0.2 g
	demin. water q.s. to	100 g



EP 0 733 357 A1

EXAMPLE 12

5

10

15

20

a.i.	<u>escin</u>	2 g
	<u>sodium heparin</u>	5.000 I.U.
	<u>diethylamine salicylate</u>	5 g
	transcutol	2 g
	colloidal silica	6 g
	ethyl alcohol	10 g
	polysorbate 80	0.50 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	camphor	0.05 g
	lavender essence	0.05 g
	demin. water q.s. to	100 g

25 EXAMPLE 13

30

35

40

45

50

55

a.i.	<u>capsaicin oleoresin 1 g (= 0.01 g capsaicin)</u>	2 g
	propylene glycol	1 g
	colloidal silica	5 g
	ethyl alcohol	2 g
	polyoxyethylen glycol 300	5 g
	polysorbate 80	0.80 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	camphor	0.2 g
	menthol	0.2 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 14

a.i.	<u>sodium heparin</u>	5.000 U.E.B.
	ethyl alcohol	10 g
	propylene glycol	10 g
	colloidal silica	6 g
	polysorbate 80	0.50 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	camphor	0.6 g
	demin. water q.s. to	100 g

EXAMPLE 15

a.i.	<u>sodium heparin</u>	10.000 I.U.
	<u>escin</u>	1 g
	phosphatidyl choline	0.8 g
	isopropyl alcohol	15 g
	propylene glycol	5 g
	colloidal silica	6 g
	polysorbate 80	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lavender essence	0.1 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 16

a.i.	<u>sodium heparin</u>	5.000 U.E.B.
	<u>jalurononidase</u>	5.000 I.U.
	<u>desametasone</u>	0.05 g
	<u>tetracaine hydrochloride</u>	0.1 g
	<u>retinol palmitate</u>	25.000 I.U.
	ethyl alcohol	2 g
	colloidal silica	3 g
	propylene glycol	10 g
	Myrj 52	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	menthol	0.1 g

EXAMPLE 17

a.i.	<u>hydrocortisone acetate</u>	0.5 g
	<u>benzocaine</u>	5 g
	<u>sodium heparin</u>	5.000 I.U.
	colloidal silica	5 g
	propylene glycol	7 g
	isopropyl myristate	3 g
	polysorbate 80	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	menthol	0.25 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 18

a.i.	<u>Hamamelis hydroalcoholic extract</u>	0.75 g
	<u>tannic acid</u>	5 g
	<u>benzalkonium chloride</u>	1 g
	ethyl alcohol	4 g
	propylene glycol	5 g
	colloidal silica	5 g
	Cetomacrogol 1000	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	bergamot oil	0.1 g
	demin. water q.s. to	100 g

EXAMPLE 19

a.i.	<u>chlorhexidine</u>	1 g
	ethyl alcohol	3 g
	isopropyl myristate	4 g
	propylene glycol	2 g
	colloidal silica	3 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	bergamot oil	0.1 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 20

a.i.	<u>benzyl alcohol</u>	4 g
	<u>benzocaine</u>	5 g
	<u>chloroxylenol</u>	0.5 g
	ethyl alcohol	5 g
	propylene glycol	8 g
	colloidal silica	5 g
	Brij 35	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	bergamot oil	0.1 g
	demin. water q.s. to	100 g

EXAMPLE 21

a.i.	<u>acyclovir</u>	5 g
	ethyl alcohol	5 g
	propylene glycol	10 g
	colloidal silica	5 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	peppermint oil	0.3 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 22

a.i.	<u>escin</u>	0.3 g
	<u>levothyroxine</u>	0.05 g
	ethyl alcohol	10 g
	propylene glycol	2 g
	colloidal silica	3,5 g
	esterified polyoxyethylene glycols	3 g
	polysorbate 80	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lily of the valley essence	0.3 g
	demin. water q.s. to	100 g

## EXAMPLE 23

a.i.	<u>vitamin E</u>	550 I.U.
	propylene glycol	1 g
	Jojoba oil	1 g
	colloidal silica	3 g
	anhydrous lanolin	1 g
	Labrafil M1944 CS	3 g
	polyoxyethylene glycol palmitostearate	2 g
	Tween 20	0.75 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	rose perfume	0.5 g
	demin. water q.s. to	100 g

EP 0 733 357 A1

EXAMPLE 24

a.i.	<u>beclometasone dipropionate</u>	10 mg
	propylene glycol	10 g
	colloidal silica	3.5 g
	polysorbate 80	0.7 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	menthol	0.3 g
	camphor	0.2 g
	demin. water q.s. to	100 g

EXAMPLE 25

a.i.	<u>2,4-dichlorobenzyl alcohol</u>	600 mg
	propylene glycol	6 g
	colloidal silica	3 g
	ethyl alcohol	10 g
	polysorbate 80	0.5 g
	sodium saccharine	0.03 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	mint essence	0.3 g
	menthol	100 mg
	balsamic flavor	1 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 26

a.i.	<u>thiocolchicoside</u>	0.25 g
	propylene glycol	7 g
	colloidal silica	3.5 g
	70% sorbitol	5.0 g
	polysorbate 80	0.5 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lavender essence	0.5 g
	demin. water q.s. to	100 g

## EXAMPLE 27

a.i.	<u>ketoprofene lysine salts</u>	15 g
	propylene glycol	5.5 g
	colloidal silica	2.5 g
	polysorbate 80	0.5 g
	methyl-p-hydroxybenzoate	0.15 g
	camphor	0.1 g
	lavender essence	0.1 g
	demin. water q.s. to	100 g

## EXAMPLE 28

a.i.	<u>sodium heparin</u>	10000 I.U.
	propylene glycol	5 g
	colloidal silica	3.5 g
	70% sorbitol	8 g
	polysorbate 80	0.5 g
	methyl-p-hydroxybenzoate	0.15 g
	nerolene lavender	0.2 g
	demin. water q.s. to	100 g



# EP 0 733 357 A1

## EXAMPLE 29

a.i.	<u>benzalkonium chloride</u>	1 g
	propylene glycol	5 g
	colloidal silica	3.5 g
	polysorbate 80	0.5 g
	methyl-p-hydroxybenzoate	0.15 g
	lavender essence	0.2 g
	lemon essence	0.4 g
	demin. water q.s. to	100 g

## EXAMPLE 30

a.i.	<u>deschlorpheniramine maleate</u>	1 g
	ethyl alcohol	3 g
	propylene glycol	5 g
	glyceryl monostearate self-emulsifier	5 g
	70% sorbitol	5 g
	colloidal silica	3.5 g
	polysorbate 80	0.7 g
	methyl-p-hydroxybenzoate	0.15 g
	rose essence	0.1 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 31

a.i.	<u>metronidazole</u>	1 g
	ethyl alcohol	5 g
	propylene glycol	10 g
	colloidal silica	3.0 g
	polysorbate 80	1 g
	methyl-p-hydroxybenzoate	0.15 g
	lily of the valley essence	0.5 g
	demin. water. q.s. to	100 g

## PARA-PHARMACEUTICAL FORMULATIONS

## EXAMPLE 32

Facial astringent masque		
a.i.	<u>Hamamelis hydroalcoholic extract</u>	5 g
	<u>nettle oily extract</u>	2 g
	propylene glycol	5 g
	colloidal silica	5 g
	polysorbate 60	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	lemon essence	0.07 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 33

5

10

15

20

## EXAMPLE 34

25

30

35

40

45

50

55

Sun shield gel		
a.i.	<u><math>\beta</math> carotene solution in vegetable oil</u>	3 g
	<u>Hypericum oily extract</u>	2 g
	propylene glycol	2 g
	colloidal silica	5 g
	polysorbate 80	1 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	sandalwood essence	0.1 g
	demin. water q.s. to	100 g

Face spray gel detergent		
a.i.	<u>sulfur glycolic solution</u>	1 g
	<u>benzoyl peroxide</u>	4 g
	isopropyl alcohol	4 g
	propylene glycol	10 g
	colloidal silica	5 g
	polysorbate 80	0.7 g
	sodium methyl-p-hydroxybenzoate	0.15 g
	rose essence	0.3 g
	demin. water q.s. to	100 g

# EP 0 733 357 A1

## EXAMPLE 35

Astringent facial masque		
a.i.	<u>Burdock hydroalcoholic extract</u>	1 g
	<u>Cornflower hydroalcoholic extract</u>	1 g
	propylene glycol	4 g
	colloidal silica	3.5 g
	polysorbate 80	0.5 g
	methyl-p-hydroxybenzoate	0.15 g
	apricot flavour	0.2 g
	demin. water q.s. to	100 g

## EXAMPLE 36

Face detergent		
a.i.	<u>Ruscus hydroalcoholic extract</u>	1 g
	<u>Asparagus hydroalcoholic extract</u>	1 g
	propylene glycol	5 g
	colloidal silica	3 g
	polysorbate 80	0.5 g
	methyl-p-hydroxybenzoate	0.15 g
	rose essence	0.3 g
	demin. water q.s. to	100 g

## Claims

1. Pharmaceutical compositions in form of thixotropic gel containing an active ingredient, from 2 to 15% of a colloidal silica, water and optionally excipients.
2. Pharmaceutical compositions according to claim 1 further comprising a solvent selected from glycerol, polyoxyethylene glycol, diethylene glycol monoalkyl ether (Transcutol™), N-methylpyrrolidone, glycofurol, isopropanol, ethylene glycol, propylene glycol in an amount from 1 to 10% by weight.
3. Pharmaceutical compositions according to claim 2, wherein the solvent is propylene glycol.
4. Pharmaceutical compositions according to any one of the previous claims, wherein the colloidal silica has a surface area ranging from 130 to 300 m<sup>2</sup>/g and an average diameter of 12 nm.
5. Pharmaceutical compositions according to any one of the previous claims, wherein the colloidal silica has a surface area ranging from 200-25 m<sup>2</sup>/g and an average diameter of 12 nm.

**EP 0 733 357 A1**

6. Formulations according to any one of the previous claims wherein the excipients are selected from surfactants, preservatives, flavouring agents, co-solvents and lipophilic phases.
7. Formulations according to any one of the previous claims, wherein water is present in an amount ranging from 60 to 97% by weight.
8. Formulations according to any one of the previous claims, further comprising a surfactant selected from sorbitan esters, polyoxyethylene sorbitan esters, polyoxyalkyl ethers, polyoxyethylene stearates.
9. Formulations according to any one of the previous claims, containing from 2 to 7% by weight of colloidal silica.
10. Spray pharmaceutical compositions containing the gels of claims 1-9 in containers with mechanical pump.

15

20

25

30

35

40

45

50

55

EP 0 733 357 A1



European Patent  
Office

EUROPEAN SEARCH REPORT

Application Number  
EP 96 10 4268

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	GB-A-1 572 032 (HOECHST UK LTD.) * claims * * example 5 *	1-10	A61K9/06 A61K47/02
A	US-A-5 214 035 (J.L. VEATCH) * the whole document *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 25 June 1996	Examiner Scarponi, U
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons</p> <p>.....  &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.82) (P4/C01)